APO Research

APO RESEARCH · REPORT

Docetaxel

Docetaxel is a chemotherapy medication used to treat a number of types of Cancer. This includes breast Cancer, head and neck Cancer, stomach Cancer, Prostate Cancer and non-small-cell lung Cancer. It may be used by itself or along with other chemotherapy medication. It is given by slow injection into a vein.

Product & engineering

Understand the product.

Docetaxel is a chemotherapy medication used to treat a number of types of Cancer. This includes breast Cancer, head and neck Cancer, stomach Cancer, Prostate Cancer and non-small-cell lung Cancer. It may be used by itself or along with other chemotherapy medication. It is given by slow injection into a vein.

Selected research

Market Outlook & Growth Opportunities

Global Docetaxel Market Outlook and Growth Opportunities 2026

Market perspective

Docetaxel is a chemotherapy medication used to treat a number of types of Cancer. This includes breast Cancer, head and neck Cancer, stomach Cancer, Prostate Cancer and non-small-cell lung Cancer. It may be used by itself or along with other chemotherapy medication. It is given by slow injection into a vein.

China Docetaxel key players include Hengrui Medicine, Sanofi, Qilu Pharma, Shenzhen Main Luck Pharma, etc. Top four companies hold a share over 80%. In terms of product, 20 mg/ml is the largest segment, with a share nearly 85%.

This report provides an overview of the global Docetaxel market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Docetaxel and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Docetaxel sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Docetaxel market size, projected growth trends, production technologies, key applications, and end-use industries.

Docetaxel Segment by Company

Hengrui Medicine

Sanofi

Qilu Pharma

Shenzhen Main Luck Pharma

Jiangsu Aosaikang Pharma

Docetaxel Segment by Type

20 mg/ml

40 mg/ml

60 mg/ml

Docetaxel Segment by Application

Breast Cancer

Prostate Cancer

Non-small Cell Lung Cancer

Others

Docetaxel Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Docetaxel status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Docetaxel market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Docetaxel significant trends, drivers, influence factors in global and regions.

6. To analyze Docetaxel competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Docetaxel market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Docetaxel and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Docetaxel.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Docetaxel market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Docetaxel industry.

Chapter 3: Detailed analysis of Docetaxel manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Docetaxel in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Docetaxel in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Docetaxel Industry Trends Table 2. Docetaxel Industry Drivers Table 3. Docetaxel Industry Opportunities and Challenges Table 4. Docetaxel Industry Restraints Table 5. Global Docetaxel Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Docetaxel Revenue Share by Company (2021-2026) Table 7. Global Docetaxel Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Docetaxel Sales Volume Share by Company (2021-2026) Table 9. Global Docetaxel Average Price (USD/Unit) of Company (2021-2026) Table 10. Global Docetaxel Company Ranking, (2024-2026) & (USD Million) Table 11. Global Docetaxel Key Company Manufacturing Base & Headquarters Table 12. Global Docetaxel Company, Product Type & Application Table 13. Global Docetaxel Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Docetaxel by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 20 mg/ml Table 18. Significant Companies of 40 mg/ml Table 19. Significant Companies of 60 mg/ml Table 20. Global Docetaxel Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Docetaxel Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Docetaxel Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Docetaxel Sales Volume Share by Type (2021-2026) Table 24. Global Docetaxel Sales Volume Share by Type (2027-2032) Table 25. Global Docetaxel Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Docetaxel Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Docetaxel Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Docetaxel Sales Value Share by Type (2021-2026) Table 29. Global Docetaxel Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Breast Cancer Table 31. Significant Companies of Prostate Cancer Table 32. Significant Companies of Non-small Cell Lung Cancer Table 33. Significant Companies of Others Table 34. Global Docetaxel Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Docetaxel Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Docetaxel Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Docetaxel Sales Volume Share by Application (2021-2026) Table 38. Global Docetaxel Sales Volume Share by Application (2027-2032) Table 39. Global Docetaxel Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Docetaxel Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Docetaxel Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Docetaxel Sales Value Share by Application (2021-2026) Table 43. Global Docetaxel Sales Value Share by Application (2027-2032) Table 44. Global Docetaxel Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Docetaxel Sales by Region (2021-2026) & (K Units) Table 46. Global Docetaxel Sales Market Share by Region (2021-2026) Table 47. Global Docetaxel Sales by Region (2027-2032) & (K Units) Table 48. Global Docetaxel Sales Market Share by Region (2027-2032) Table 49. Global Docetaxel Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Docetaxel Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Docetaxel Sales Value Share by Region (2021-2026) Table 52. Global Docetaxel Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Docetaxel Sales Value Share by Region (2027-2032) Table 54. Global Docetaxel Market Average Price (USD/Unit) by Region (2021-2026) Table 55. Global Docetaxel Market Average Price (USD/Unit) by Region (2027-2032) Table 56. Global Docetaxel Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Docetaxel Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Docetaxel Sales by Country (2021-2026) & (K Units) Table 59. Global Docetaxel Sales Market Share by Country (2021-2026) Table 60. Global Docetaxel Sales by Country (2027-2032) & (K Units) Table 61. Global Docetaxel Sales Market Share by Country (2027-2032) Table 62. Global Docetaxel Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Docetaxel Sales Value Market Share by Country (2021-2026) Table 64. Global Docetaxel Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Docetaxel Sales Value Market Share by Country (2027-2032) Table 66. Hengrui Medicine Company Information Table 67. Hengrui Medicine Business Overview Table 68. Hengrui Medicine Docetaxel Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 69. Hengrui Medicine Docetaxel Product Portfolio Table 70. Hengrui Medicine Recent Development Table 71. Sanofi Company Information Table 72. Sanofi Business Overview Table 73. Sanofi Docetaxel Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 74. Sanofi Docetaxel Product Portfolio Table 75. Sanofi Recent Development Table 76. Qilu Pharma Company Information Table 77. Qilu Pharma Business Overview Table 78. Qilu Pharma Docetaxel Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 79. Qilu Pharma Docetaxel Product Portfolio Table 80. Qilu Pharma Recent Development Table 81. Shenzhen Main Luck Pharma Company Information Table 82. Shenzhen Main Luck Pharma Business Overview Table 83. Shenzhen Main Luck Pharma Docetaxel Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 84. Shenzhen Main Luck Pharma Docetaxel Product Portfolio Table 85. Shenzhen Main Luck Pharma Recent Development Table 86. Jiangsu Aosaikang Pharma Company Information Table 87. Jiangsu Aosaikang Pharma Business Overview Table 88. Jiangsu Aosaikang Pharma Docetaxel Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 89. Jiangsu Aosaikang Pharma Docetaxel Product Portfolio Table 90. Jiangsu Aosaikang Pharma Recent Development Table 91. Key Raw Materials Table 92. Raw Materials Key Suppliers Table 93. Docetaxel Distributors List Table 94. Docetaxel Customers List Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. Docetaxel Product Image Figure 2. Global Docetaxel Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Docetaxel Sales Value (2021-2032) & (US$ Million) Figure 4. Global Docetaxel Sales (2021-2032) & (K Units) Figure 5. Global Docetaxel Sales Average Price (USD/Unit) & (2021-2032) Figure 6. Global Docetaxel Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 20 mg/ml Image Figure 10. 40 mg/ml Image Figure 11. 60 mg/ml Image Figure 12. Global Docetaxel Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Docetaxel Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Docetaxel Sales Volume Share by Type (2021-2032) Figure 15. Global Docetaxel Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Docetaxel Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Docetaxel Sales Value Share by Type (2021-2032) Figure 18. Breast Cancer Image Figure 19. Prostate Cancer Image Figure 20. Non-small Cell Lung Cancer Image Figure 21. Others Image Figure 22. Global Docetaxel Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Docetaxel Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Docetaxel Sales Volume Share by Application (2021-2032) Figure 25. Global Docetaxel Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Docetaxel Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Docetaxel Sales Value Share by Application (2021-2032) Figure 28. Global Docetaxel Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Docetaxel Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Docetaxel Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Docetaxel Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Docetaxel Sales Value (2021-2032) & (US$ Million) Figure 33. North America Docetaxel Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Docetaxel Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Docetaxel Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Docetaxel Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Docetaxel Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Docetaxel Sales Value (2021-2032) & (US$ Million) Figure 39. South America Docetaxel Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Docetaxel Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Docetaxel Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Docetaxel Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Docetaxel Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Docetaxel Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Docetaxel Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Docetaxel Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • 20 mg/ml
  • 40 mg/ml
  • 60 mg/ml
Applications
  • Breast Cancer
  • Prostate Cancer
  • Non-small Cell Lung Cancer
  • Others
Companies covered
  • Hengrui Medicine
  • Sanofi
  • Qilu Pharma
  • Shenzhen Main Luck Pharma
  • Jiangsu Aosaikang Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Docetaxel Sales Value (2021-2032)
  4. 1.2.2 Global Docetaxel Sales Volume (2021-2032)
  5. 1.2.3 Global Docetaxel Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Docetaxel Market Dynamics
  1. 2.1 Docetaxel Industry Trends
  2. 2.2 Docetaxel Industry Drivers
  3. 2.3 Docetaxel Industry Opportunities and Challenges
  4. 2.4 Docetaxel Industry Restraints
3 Docetaxel Market by Company
  1. 3.1 Global Docetaxel Company Revenue Ranking in 2025
  2. 3.2 Global Docetaxel Revenue by Company (2021-2026)
  3. 3.3 Global Docetaxel Sales Volume by Company (2021-2026)
  4. 3.4 Global Docetaxel Average Price by Company (2021-2026)
  5. 3.5 Global Docetaxel Company Ranking (2024-2026)
  6. 3.6 Global Docetaxel Company Manufacturing Base and Headquarters
  7. 3.7 Global Docetaxel Company Product Type and Application
  8. 3.8 Global Docetaxel Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Docetaxel Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Docetaxel Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Docetaxel Market by Type
  1. 4.1 Docetaxel Type Introduction
  2. 4.1.1 20 mg/ml
  3. 4.1.2 40 mg/ml
  4. 4.1.3 60 mg/ml
  5. 4.2 Global Docetaxel Sales Volume by Type
  6. 4.2.1 Global Docetaxel Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Docetaxel Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Docetaxel Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Docetaxel Sales Value by Type
  10. 4.3.1 Global Docetaxel Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Docetaxel Sales Value by Type (2021-2032)
  12. 4.3.3 Global Docetaxel Sales Value Share by Type (2021-2032)
5 Docetaxel Market by Application
  1. 5.1 Docetaxel Application Introduction
  2. 5.1.1 Breast Cancer
  3. 5.1.2 Prostate Cancer
  4. 5.1.3 Non-small Cell Lung Cancer
  5. 5.1.4 Others
  6. 5.2 Global Docetaxel Sales Volume by Application
  7. 5.2.1 Global Docetaxel Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Docetaxel Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Docetaxel Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Docetaxel Sales Value by Application
  11. 5.3.1 Global Docetaxel Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Docetaxel Sales Value by Application (2021-2032)
  13. 5.3.3 Global Docetaxel Sales Value Share by Application (2021-2032)
6 Docetaxel Regional Sales and Value Analysis
  1. 6.1 Global Docetaxel Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Docetaxel Sales by Region (2021-2032)
  3. 6.2.1 Global Docetaxel Sales by Region: 2021-2026
  4. 6.2.2 Global Docetaxel Sales by Region (2027-2032)
  5. 6.3 Global Docetaxel Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Docetaxel Sales Value by Region (2021-2032)
  7. 6.4.1 Global Docetaxel Sales Value by Region: 2021-2026
  8. 6.4.2 Global Docetaxel Sales Value by Region (2027-2032)
  9. 6.5 Global Docetaxel Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Docetaxel Sales Value (2021-2032)
  12. 6.6.2 North America Docetaxel Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Docetaxel Sales Value (2021-2032)
  15. 6.7.2 Europe Docetaxel Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Docetaxel Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Docetaxel Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Docetaxel Sales Value (2021-2032)
  21. 6.9.2 South America Docetaxel Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Docetaxel Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Docetaxel Sales Value Share by Country, 2025 VS 2032
7 Docetaxel Country-level Sales and Value Analysis
  1. 7.1 Global Docetaxel Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Docetaxel Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Docetaxel Sales by Country (2021-2032)
  4. 7.3.1 Global Docetaxel Sales by Country (2021-2026)
  5. 7.3.2 Global Docetaxel Sales by Country (2027-2032)
  6. 7.4 Global Docetaxel Sales Value by Country (2021-2032)
  7. 7.4.1 Global Docetaxel Sales Value by Country (2021-2026)
  8. 7.4.2 Global Docetaxel Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Docetaxel Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Docetaxel Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Docetaxel Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Docetaxel Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Docetaxel Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Docetaxel Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Docetaxel Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Docetaxel Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Docetaxel Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Docetaxel Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Docetaxel Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Docetaxel Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Docetaxel Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Docetaxel Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Docetaxel Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Docetaxel Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Docetaxel Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Docetaxel Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Docetaxel Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Docetaxel Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Docetaxel Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Docetaxel Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Docetaxel Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Docetaxel Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Docetaxel Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Docetaxel Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Docetaxel Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Docetaxel Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Docetaxel Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Docetaxel Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Docetaxel Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Docetaxel Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Docetaxel Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Docetaxel Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Docetaxel Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Docetaxel Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Docetaxel Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Docetaxel Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Docetaxel Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Docetaxel Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Docetaxel Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Docetaxel Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Docetaxel Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Docetaxel Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Docetaxel Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Docetaxel Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Docetaxel Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Docetaxel Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Docetaxel Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Docetaxel Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Docetaxel Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Docetaxel Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Docetaxel Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Docetaxel Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Docetaxel Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Docetaxel Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Docetaxel Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Docetaxel Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Docetaxel Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Docetaxel Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Docetaxel Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Docetaxel Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Docetaxel Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Docetaxel Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Docetaxel Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Docetaxel Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Docetaxel Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Docetaxel Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Docetaxel Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Docetaxel Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Docetaxel Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Docetaxel Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Docetaxel Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Docetaxel Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Docetaxel Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Docetaxel Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Docetaxel Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Docetaxel Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Docetaxel Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Docetaxel Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Docetaxel Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Docetaxel Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Docetaxel Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Docetaxel Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Hengrui Medicine
  2. 8.1.1 Hengrui Medicine Company Information
  3. 8.1.2 Hengrui Medicine Business Overview
  4. 8.1.3 Hengrui Medicine Docetaxel Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Hengrui Medicine Docetaxel Product Portfolio
  6. 8.1.5 Hengrui Medicine Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Docetaxel Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Docetaxel Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Qilu Pharma
  14. 8.3.1 Qilu Pharma Company Information
  15. 8.3.2 Qilu Pharma Business Overview
  16. 8.3.3 Qilu Pharma Docetaxel Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Qilu Pharma Docetaxel Product Portfolio
  18. 8.3.5 Qilu Pharma Recent Developments
  19. 8.4 Shenzhen Main Luck Pharma
  20. 8.4.1 Shenzhen Main Luck Pharma Company Information
  21. 8.4.2 Shenzhen Main Luck Pharma Business Overview
  22. 8.4.3 Shenzhen Main Luck Pharma Docetaxel Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Shenzhen Main Luck Pharma Docetaxel Product Portfolio
  24. 8.4.5 Shenzhen Main Luck Pharma Recent Developments
  25. 8.5 Jiangsu Aosaikang Pharma
  26. 8.5.1 Jiangsu Aosaikang Pharma Company Information
  27. 8.5.2 Jiangsu Aosaikang Pharma Business Overview
  28. 8.5.3 Jiangsu Aosaikang Pharma Docetaxel Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Jiangsu Aosaikang Pharma Docetaxel Product Portfolio
  30. 8.5.5 Jiangsu Aosaikang Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Docetaxel Value Chain Analysis
  2. 9.1.1 Docetaxel Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Docetaxel Sales Mode & Process
  6. 9.2 Docetaxel Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Docetaxel Distributors
  9. 9.2.3 Docetaxel Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research